Efficacy And Safety Of A New Clobetasol Propionate 0.05% Foam In Alopecia Areata: A Randomized, Double-Blind Placebo-Controlled Trial
October 2006
in “
Journal of the European Academy of Dermatology and Venereology
”
TLDR The new clobetasol propionate foam is effective and safe for treating alopecia areata.
The study evaluated the efficacy, safety, and tolerability of a new clobetasol propionate 0.05% foam (CF) in treating moderate to severe alopecia areata (AA) in a 24-week randomized, double-blind, placebo-controlled trial involving 34 patients. Results showed that 89% of CF-treated sites experienced greater hair regrowth compared to 11% of placebo-treated sites. The hair regrowth score (RGS) was significantly higher in CF-treated sites (1.2 ± 1.6) than in placebo-treated sites (0.4 ± 0.8). By the end of the trial, 47% of CF-treated patients had a RGS of 2 or higher, indicating more than 25% hair regrowth. The treatment was well-tolerated with minimal side effects, such as folliculitis in two patients, and no significant changes in cortisol and ACTH levels. The study concluded that the new clobetasol propionate foam is an effective, safe, and well-tolerated treatment for AA with good patient compliance.